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Abstract
Macrophage-associated cytokines play an important role in cancer metastasis; however, the functions of interleukins (IL) 
6 and 10 in breast cancer (BC) progression and metastasis are not clear. In this study the roles of IL-6/IL-10 in regulating 
vascular invasion and their prognostic significance in BC are investigated. MDA-MB-231 and MCF-7 migration (± IL-6 or 
IL-10) was assessed by scratch wound assay. Cancer cell adhesion to IL-6/IL-10 stimulated blood and lymphatic endothelial 
cells (EC) was investigated. Expression of IL-6 /IL-10 was assessed using immunohistochemistry in an annotated cohort of 
early stage BC (n = 1380) and associations with clinicopathological variables and clinical outcome evaluated. IL-6 did not 
alter BC cell migration however a dose-dependent inhibition in MDA-MB-231 migration with IL-10 treatment was observed 
(P = 0.03). BC cells were more adhesive to blood vs lymphatic EC, however, IL-6/IL-10 had no effect on adhesion patterns. 
High expression of IL-6/IL-10 was associated with clinicopathological criteria (e.g. hormone receptor status, all P < 0.05), 
improved disease-free survival (DFS; P < 0.05) and improved BC-specific survival (BCSS; only IL-6, P = 0.017). However, 
neither IL-6 nor IL-10 expression were independent prognostic factors from multivariate analysis. In BC subgroups, IL-6 
and IL-10 were good prognosticators in terms of DFS in non-basal, non-triple-negative (non-TN), ER-positive, PgR-positive 
(only IL-10), and Her-2-negative (only IL-6) BC (all P < 0.05). IL-6 was associated with improved BCSS in non-basal, ER-
positive and non-TN BC (all P < 0.05).
Keywords Breast cancer · IL-6 · IL-10 · Macrophage-associated cytokines · Metastasis
Abbreviations
BC  Breast cancer
BCSS  Breast cancer-specific survival
DAB  Diaminobenzidine
DBS  Donor bovine serum
DFS  Disease-free survival
EGF  Epidermal growth factor
ER  Oestrogen receptor
hMEC-1  Human microvascular endothelial cells
hTERT-LEC  Human telomerase reverse transcriptase 
immortalised lymphatic endothelial cells
IHC  Immunohistochemistry
IL  Interleukin
KM  Kaplan–Meier
LVI  Lymphovascular invasion
M1s  Type-1 proinflammatory macrophages
M2s  Type-2 anti-inflammatory macrophages
NPI  Nottingham Prognostic Index
PgR  Progesterone receptor
REMARK  Reporting recommendations for tumour 
marker prognostic studies
rIL  Recombinant interleukin
STAT3  Signal transducer and activator of transcrip-
tion 3
TMA  Tissue microarray
TN  Triple negative
Narmeen Ahmad and Aula Ammar have contributed equally to 
this work.
Electronic supplementary material The online version of this 
article (https://doi.org/10.1007/s00262-017-2106-8) contains 
supplementary material, which is available to authorized users.
 * Stewart G. Martin 
 stewart.martin@nottingham.ac.uk
1 Division of Cancer and Stem Cells, Academic Clinical 
Oncology, School of Medicine, University of Nottingham, 
Nottingham University Hospitals NHS Trust, City Hospital 
Campus, Hucknall Road, Nottingham NG5 1PB, UK
2 Division of Cancer and Stem Cells, Histopathology, School 
of Medicine, University of Nottingham, Nottingham 
University Hospitals NHS Trust, City Hospital Campus, 
Hucknall Road, Nottingham NG5 1PB, UK
 Cancer Immunology, Immunotherapy
1 3
Background
The presence of lymph node (LN) metastasis in breast 
cancer (BC) is associated with poor overall survival with 
recent studies showing that lymphatic vessel invasion (LI) 
rather than blood vessel invasion (BI) is the predominant 
form of lymphovascular invasion (LVI) in early stage inva-
sive BC [1, 2]. Tumours with high densities of inflam-
matory infiltrate have a higher percentage of proliferating 
lymphatic vessels and LN metastasis [1, 3]. Macrophages 
represent a significant population of the inflammatory 
infiltrate and are linked to BC malignancy [4]. They can 
polarise into M1s, a pro-inflammatory anti-tumour type, or 
M2s, an anti-inflammatory form. The presence of inflam-
matory cytokines in the tumour milieu influences a num-
ber of processes at different stages of tumour progression, 
including initiation, proliferation, promotion, tumour cell 
conversion, angiogenesis, invasion, inhibition of apoptosis, 
immune surveillance, drug resistance and metastasis [5]. 
Comparatively little is known, however, about the roles of 
the macrophage-associated cytokines Interleukin-6 (IL-6) 
and interleukin-10 (IL-10) in the regulation of LVI, and 
LN metastasis or even their expression in breast tumours.
IL-6 is a pleiotropic cytokine that plays important roles 
in immune response, inflammation, and haematopoiesis. It 
is produced by a variety of normal cells including mono-
cytes and macrophages [6], but is also expressed by multi-
ple tumour tissue types, such as breast, prostate, colorectal 
and ovarian cancer [7–10]. IL-6 may also play an impor-
tant role in various aspects of tumour behaviour, including 
apoptosis, tumour growth cell proliferation, migration and 
invasion, angiogenesis and metastasis [11].
IL-10, initially termed ‘cytokine synthesis inhibitor’ 
or ‘cytokine inhibitory factor’ due to its inhibitory action 
on cytokine production by T helper cells, is produced by 
almost all leukocytes, as well as numerous human tumour 
cells including breast, kidney, colon, pancreas, malignant 
melanomas and neuroblastomas [12–17]. It belongs to the 
IL-10 family of cytokines and plays a role in the pathogen-
esis of infectious disease and inflammation. IL-10 is essen-
tial to suppress tumour promoting inflammation mediators 
(reviewed in [18]); however, IL-10 might play a potential 
role in regulating tumour angiogenesis [19].
Both IL-6 and IL-10 signal through the signal trans-
ducer and activator of transcription 3 (STAT3) [20]. 
Although signalling mainly through STAT3, IL-6 is pro-
inflammatory whereas IL-10 is anti-inflammatory and sup-
presses the expression of other cytokines by immune cells. 
Such responses have been explained in dendritic cells by 
temporal activation of STAT3 by IL-6 vs prolonged effect 
of IL-10 via suppressor of cytokine signalling-3 (SOCS3) 
activation [20].
The role of the macrophage-associated cytokines IL-6 
and IL-10 in LVI or LN metastasis has not been previously 
addressed. There is little information available about the 
in vitro effect of IL-6 and IL-10 on the phenotypic behaviour 
of BC cells in terms of tumour cell migration or adhesion to 
lymphatic and blood endothelium, which are key steps in the 
metastatic process. Equally, the prognostic significance of 
BC tissue expression of these cytokines has not been previ-
ously investigated in a large cohort of patient samples. The 
aim of this study was to assess the effect of IL-6 and IL-10 
on BC cell migration and endothelial adhesion, examining 
for differential effects on blood vs lymphatic endothelium, 
as well as assessing the prognostic significance of IL-6 and 
IL-10 expression in a large cohort of BC patients.
Methods
Cell lines and culture
BC cell lines MCF-7 (luminal phenotype) and MDA-
MB-231 [basal/triple negative (TN) phenotype], human 
microvascular endothelial cells hMEC-1 (passage window 
4–18), human telomerase reverse transcriptase immortalised 
lymphatic EC (hTERT-LEC, passage window 27–34) [21] 
were used in this study. BC cell lines were used across a 
10-passage window. MCF-7 cells were cultured in RPMI 
supplemented with penicillin/streptomycin (100 U/mL and 
0.01 mg/mL, respectively) and 10% iron supplemented 
donor bovine serum (DBS, Gibco). MDA-MB-231s were 
cultured in MEM supplemented with l-glutamine (2 mM), 
non-essential amino acids (0.1 mM) and 10% iron-sup-
plemented DBS. hMEC-1 were grown in EMB-2 (Lonza) 
containing EGF (0.01 µg/mL), hydrocortisone (5 µg/mL, 
Sigma), penicillin/streptomycin and 10% iron-supplemented 
DBS; and hTERT-LEC grown in EGM-2MV kit (Lonza). 
All cells were mycoplasma free and tumour cell line authen-
tication conducted by short tandem repeat verification (Pow-
erPlex 16, Promega).
Scratch wound migration assay
Methodology was described in detail elsewhere [22] with the 
following concentrations of cytokines being used to stimu-
late tumour cells (IL-6 at 2.5, 5, or 10 ng/mL; or IL-10 at 
5, 10, or 15 ng/mL, Peprotech). Wound closure was meas-
ured using photomicrographs taken at 0, 2, 4, 6, and 24 h at 
× 100 magnification. The percentage reduction of the scratch 
area at different time points represented the level of cellular 
migration and was measured using ImageJ 1.46e (National 
Institute of Health, USA). Experiments were conducted 
three times, each in triplicate.
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Static adhesion assay
Assay methodology was described in detail previously [22]. 
Briefly, a confluent endothelial monolayer remained unstim-
ulated, or was stimulated for 24 h either with IL-6 (2.5, 5 
or 10 ng/mL) or IL-10 (5, 10, or 15 ng/mL). Tumour cells 
were fluorescently labelled with 1 µM of Cell Tracker Green 
CMFDA (Invitrogen) for 30 min at 37C, then 1 × 105cells/
well (24-well plate) added for 35 min. Non-adherent tumour 
cells were washed and adherent cells counted using a fluo-
rescence microscope (Nikon) in two fields of view/well at 
× 100 magnification. Experiments were conducted three 
times, each in duplicate. As a positive control, adhesion of 
peripheral blood mononuclear cells (PBMCs, isolated from 
whole blood using a density gradient centrifugation method) 
to EC stimulated with and without 5 ng/mL TNF-α (Pepro-
tech) for 24 h was always performed directly prior to tumour 
cell adhesion assay to assess the responsiveness of EC to 
cytokine stimulation as described previously [22].
Patient samples
A total of 1380 patients with early stage invasive BC, 
treated at Nottingham University Hospitals between 1988 
and 1998 with long-term follow-up, were included. Data 
on a wide range of clinicopathological markers, receptor 
status, and many different biomarkers including LVI have 
been described previously [1, 2]. The median age of patients 
was 55 years (ranging from 18 to 70 years). Patients were 
managed under a uniform protocol, where all underwent 
mastectomy or wide local excision followed by radiotherapy. 
The clinicopathological features of the patients and tumours 
used in the analysis are shown in Table 1.
BC-specific survival (BCSS) was defined as the time 
interval (in months) between the start of primary surgery to 
death resultant from BC. Disease-free survival (DFS) time 
was defined as the time interval (in months) between the pri-
mary surgery and first recurrence of cancer. The mean sur-
vival time of the cohort of patients was 225.4 months. This 
study is reported in accordance with REMARK criteria [23]. 
Ethical approval was granted by Nottingham Research Eth-
ics Committee 2 under the title ‘Development of a molecu-
lar genetic classification of breast cancer’ (C202313) and 
by Nottingham Research Ethics Committee under the title 
‘Blood tumour markers in breast cancer’.
Immunohistochemistry (IHC)
Information on tissue microarray (TMA) construction is pro-
vided elsewhere [24]. Freshly cut 4-μm formalin-fixed paraf-
fin-embedded breast cancer TMA sections were deparaffin-
ised and rehydrated using xylene, industrial methylated spirit 
and water. Antigen retrieval was performed by microwaving 
Table 1  Clinicopathological characteristics of patients (n = 1380)
Clinical features Number (%)
Age (years)
 ≤ 40 119 (8.6)
 > 40 1261 (91.4)
Stage
 I 829 (60.1)
 II 418 (30.3)
 III 125 (9.1)
 ND 8 (0.6)
LI
 Negative 752 (54.5)
 Positive 383 (327.8)
 ND 245 (17.8)
NPI
 Good (< 3.4) 418 (30.3)
 Moderate (3.4–5.4) 696 (50.4)
 Poor (> 5.4) 255 (18.5)
 ND 11 (0.8)
PgR status
 Negative 532 (38.6)
 Positive 774 (56.1)
 ND 74 (5.4)
Basal like status
 Non-basal 1026 (74.3)
 Basal like 268 (19.4)
 ND 86 (6.2)
Recurrence
 No 945 (68.5)
 Yes 426 (30.9)
 ND 9 (0.7)
Size (cm)
 ≤ 2 824 (61.0)
 < 2 529 (38.3)
 ND 9 (0.7)
Grade
 I 235 (17)
 II 468 (33.9)
 III 668 (48.3)
 ND 9 (0.7)
BI
 Negative 705 (51.5)
 Positive 3 (0.2)
 ND 672 (48.7)
ER status
 Negative 337 (24.4)
 Positive 1002 (72.6)
 ND 41 (3.0)
Her-2 status
 Negative 1172 (84.9)
 Positive 184 (13.3)
 ND 24 (1.7)
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samples in citrate buffer (pH = 6) at 750 W for 10 min, fol-
lowed by 10 min at 450 W. Endogenous peroxidase activity 
was blocked with 10%  H2O2 in methanol for 10 min, fol-
lowed by treatment with normal horse serum (1:50, Vector 
laboratories) for 30 min. Polyclonal goat anti-IL-6 (1:25, 
R&D systems) or goat anti-IL-10 (1:100, R&D systems) 
were then incubated for 1 h at room temperature with the 
tissues. Secondary antibody was added for 1 h, followed 
by treatment with Vectastain Goat Elite ABC kit (Vector 
Laboratories) for 30 min. DAB substrate was added and 
slides were counter-stained with haematoxylin. Tonsil sec-
tions were used as a positive control. For negative controls, 
the staining protocol was performed, but primary antibody 
omitted.
IL-6 and IL-10 antibody specificity was confirmed 
through peptide blocking experiments. Anti-IL-6 or anti-
Il-10 antibody was neutralised with recombinant human 
IL-6 (rIL-6, 1 µg) or rIL-10 (2 µg) (Peprotech) overnight 
at 4 °C and the same staining protocol then carried out as 
above. TMA stained slides were scanned using a Nano-
zoomer Digital Pathology scanner (Hamamatsu Photonics) 
at × 200 magnification. H-scores were calculated by multi-
plying the percentage area scoring positive by the respective 
intensity using the following formula: (% of cells stained 
weak × 1) + (% of cells stained moderate × 2) + (% of cells 
stained strong × 3) (range 0–300) [25]. The core was con-
sidered assessable if tumour cells were present in > 40% 
of its total area. 30% of cores were examined by a second 
independent assessor blinded to scores and clinicopathologi-
cal data with good concordance between both scorers (single 
measurement intra-class correlation of 0.816 for IL-6 and 
0.714 for IL-10). Immunohistochemical scores were dichot-
omised based on BCSS analysis using X-tile software (a free 
bioinformatics-based tool developed by Yale University to 
provide cut-points in an independent and an unbiased way) 
[26].
Statistical analysis
Data are presented as mean ± standard deviation (SD) for 
adhesion and migration endpoints. A one-way ANOVA 
test was used to assess significance between the different 
cytokine concentrations at a given time point followed by a 
paired t test when the ANOVA test showed significance. For 
immunohistochemistry, the relationship between categorised 
protein expression and clinicopathological data was meas-
ured using the Pearson Chi-squared test of association (χ2) 
or Fisher’s exact test. Pearson correlation was used to assess 
the correlation between IL-6 and IL-10 expression, and the 
Spearman’s rank correlation test was used to assess correla-
tion between IL-6/IL-10 and STAT3 expression (assessed 
previously [27]). Survival curves were plotted using the 
Kaplan–Meier (KM) method and the statistical significance 
between groups determined by the log-rank test. Multivari-
ate survival analysis was performed by Cox proportional 
hazards analysis with data adjusted to include potential con-
founding factors that were individually significantly asso-
ciated with survival from KM analysis and log-rank test. 
P < 0.05 was considered statistically significant. Statistical 
analysis was performed using SPSS 22.0 software (IBM 
SPSS Statistics).
Results
IL‑6 has no significant effect on cell migration
Under unstimulated conditions, the migration of MDA-
MB-231 was higher than that of MCF-7 cells (percentage 
wound closures were 65 ± 9 vs. 39 ± 13%, respectively, at 
24 h). After 24 h treatment, low doses of IL-6 (2.5 ng/mL) 
caused a slight increase in MDA-MB-231 migration in com-
parison to unstimulated cells, whereas higher doses (i.e. 5 
and 10 ng/mL) were associated with slower migration but 
no statistical significance was observed (P = 0.27, ANOVA 
test) (Fig. 1a). Similarly, IL-6 treatment caused a marginal, 
but non-significant, decrease in MCF-7 migration at 24 h 
treatment (P = 0.51, ANOVA test, Fig. 1b).
IL‑10 has an inhibitory effect on migration in vitro
A dose-dependent decrease in MDA-MB-231 migration 
was seen with increasing concentrations of IL-10, with 
a weak but significant difference seen at 15 ng/mL in 
comparison to control (P = 0.03). The percentage wound 
closure at 24  h was 63 ± 7, 60 ± 6, and 56 ± 4% when 
LI lymphatic vessel invasion, BI blood vessel invasion, NPI Not-
tingham Prognostic Index, ER oestrogen receptor, PgR progesterone 
receptor, Her-2 epidermal growth factor receptor 2, TN triple nega-
tive, ND not determined
Table 1  (continued)
Clinical features Number (%)
TN status
 Non-TN 1114 (80.7)
 TN 233 (16.2)
 ND 43 (3.1)
Distant metastasis
 No 945 (68.5)
 Yes 426 (30.9)
 ND 9 (0.7)
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cells were treated with 5, 10, and 15 ng/mL, respectively, 
compared to 70 ± 3% wound closure with control cells 
(Fig. 1c). The percentage closure with MCF-7 cells, at 
24 h post wounding, was 24 ± 10, 22 ± 10, and 19 ± 8% 
when cells were treated with 5, 10, and 15 ng/mL com-
pared to control, at 23 ± 7% (Fig. 1d).
IL‑6 and IL‑10 do not affect tumour–endothelial cell 
adhesion
As observed previously [22] tumour cells show a pref-
erence for adhesion to blood rather than lymphatic 
endothelium. Both MDA-MB-231 and MCF-7 adhesion 
to hMEC-1-was approximately 50% higher than adhesion 
to hTERT-LEC under unstimulated conditions (Fig. 2) 
with MDA-MB-231 showing higher affinity than MCF-7 
to EC. Pre-stimulation of hMEC-1 or hTERT-LEC with 
either IL-6 or IL-10 did not significantly alter tumour cell 
adhesion patterns when compared to unstimulated condi-
tions (Fig. 2).
Expression of IL‑6 and IL‑10 in breast tumour 
specimens
Both IL-6 and IL-10 showed positive cytoplasmic staining 
in BC cells with a heterogeneous staining pattern between, 
as well as within, certain tumour cores varying from weak 
to intense. Representative photomicrographs of staining 
intensity of IL-6 and IL-10 expression in BC are shown 
in Fig. 3a–f. The specificity of IL-6 and IL-10 antibodies 
was confirmed using blocking rIL-6 or rIL-10 as shown in 
Fig. 3g, h, j, k, respectively. In certain specimens, expression 
of these cytokines was observed in a subset of inflamma-
tory cells but this expression was not quantified (Fig. 3i, l, 
respectively).
The median H-scores for IL-6 (n = 1191) and IL-10 
(n = 878) expression were 80 (ranging between 0 and 275) 
and 170 (ranging between 60 and 265), respectively. IL-6 
cut-point for stratification was 95, with 349 (29.3%) cases 
showing high expression. The IL-10 cut-point was 180 
with 150 (17.1%) with high expression. The expression of 
IL-6 and IL-10 were positively and significantly correlated 
Fig. 1  Effect of recombinant human IL-6 or IL-10 stimulation 
on breast cancer cell migration rate. IL-6 treatment caused a slight 
decrease in MDA-MB-231 (a) and MCF-7 (b) migration after 24  h 
treatment; however, the reduction in migration did not reach statisti-
cal significance. IL-10 (15 ng/mL) was associated with a significant 
reduction in MDA-MB-231 migration (P = 0.03) (c), but has no 
significant effect on MCF-7 migration (d). Data are presented as 
mean ± SD of three independent experiments each carried out in trip-
licate, and P values evaluated by paired sample t test (asterisk repre-
sent a significant P value)
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(Pearson correlation, r = 0.279, P < 0.001, n = 689). IL-6 
was positively correlated with nuclear (r = 0.142, P < 0.001, 
n = 836) and cytoplasmic (r = 0.292, P < 0.001, n = 852) 
STAT3. IL-10 was similarly positively correlated with 
nuclear and cytoplasmic STAT3 (r = 0.221, P < 0.001, 
n = 643 and r = 0.235, P < 0.001, n = 655, respectively).
Dichotomised data were tested for associations with clin-
icopathological criteria (Table 1). There was no significant 
relationship between IL-6 expression and either stage, LN 
involvement or LVI that had been previously assessed by 
immunohistochemistry [1–3]. However, high IL-6 expres-
sion was significantly associated with patients over 40 years 
(P = 0.033), lower tumour size (P = 0.006), lower tumour 
grade (P = 0.001), lower Nottingham Prognostic Index (NPI) 
scores (P < 0.001), positive oestrogen receptor (ER) status 
(P = 0.046), and positive progesterone receptor (PgR) status 
(P < 0.001) (Table 2). As with IL-6 there was no significant 
relationship between IL-10 with either stage, LN metastasis 
or IHC determined LVI (Table 2). High IL-10 expression 
was, however, significantly associated with lower tumour 
grade (P < 0.001), low NPI value (P < 0.001), positive 
ER (P < 0.001), positive PgR (P < 0.001), negative Her-2 
(P = 0.003) as well as non-TN status (P = 0.003).
The median values of IL-6 and IL-10 expression (80 
and 170, respectively) were also used as cut-point values 
to dichotomise the data into high and low expression of the 
cytokine. Using the median as a cut-point and Mann–Whit-
ney or Kruskal–Wallis as a statistical test, similar results 
were obtained to those observed with the X-tile cut-point 
values. IL-6 was significantly associated with younger age 
and smaller tumour size (P = 0.002 and P = 0.007, respec-
tively) and both IL-6 and IL-10 were significantly associated 
with lower grade (P < 0.001 and P = 0.001, respectively), 
lower NPI (both P < 0.001), positive ER and PgR status 
(all P < 0.001, respectively) and with non-TN status (both 
P < 0.001). High IL-10 expression was also associated with 
negative Her-2 status (P = 0.003).
High IL‑6/IL‑10 expression is associated 
with improved survival
Survival analyses show that high IL-6 expression is associ-
ated with better DFS (P = 0.007) (Fig. 4a). The mean DFS 
was 158.2 months in patients with high IL-6 in compari-
son to 151.268 months in patients with low expression of 
IL-6. IL-6 expression was also associated with better BCSS 
Fig. 2  Effect of IL-6 and IL-10 on endothelial adhesion patterns 
of MDA-MB-231 and MCF-7. IL-6 or IL-10 stimulation of blood 
(hMEC-1) and lymphatic (hTERT-LEC) endothelial cells did not 
significantly alter adhesion patterns compared to the unstimulated 
controls. a MDA-MB-231 and b MCF-7 adhesion to IL-6 stimulated 
endothelial cells, c MDA-MB-231 and d MCF-7 adhesion to IL-10 
stimulated endothelia. Data represent the mean of adhered cells ± SD 
of three independent experiments, each carried out in duplicate 
(n = 6)
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(P = 0.017) (Fig. 4b) with a mean of 238.071 versus 218.742 
months survival time in the high and low IL-6 groups, 
respectively. Similarly, high IL-10 expression was associ-
ated with better DFS (P = 0.027) (Fig. 4c) and the mean 
DFS time was 166.132 months for high IL-10 in comparison 
to 150.336 months in patients with low IL-10 expression. 
However, IL-10 expression was not associated with BCSS 
(P = 0.150) (Fig. 4d). In multivariate Cox regression analysis 
the following factors were included in the analysis: patient 
age, tumour size, tumour stage, tumour grade, NPI, ER, PgR 
and Her-2 status, LVI, and LN status (all were significant 
with regard to survival analysis with P values < 0.001 for 
Fig. 3  IL-6 and IL-10 expression in breast cancer and stromal cells. 
Representative images of tumour staining with IL-6 (a–c) and IL-10 
(d–f). Staining pattern: a, d weak, b, e moderate, and c, f strong. g, 
h, j, k Representative images of specificity tests of IL-6 and IL-10 
antibodies, respectively: BC staining with IL-6 antibody (g) or IL-6 
antibody blocked overnight with 1 µg of rIL-6 (h); BC staining with 
IL-10 antibody alone (j) or IL-10 antibody blocked overnight with 
2 µg of rIL-10 (k). Examples of stromal expression of IL-6 and IL-10 
are shown in i, l, respectively (black arrows). Photomicrographs: a–f; 
× 100 and g–l × 200 magnification; inset boxes at × 200 magnifica-
tion; scale bars 100 µm
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Table 2  Association between 
IL-6/IL-10 expression and 
clinicopathological variables
Data are presented as absolute numbers. P values are resultant from Pearson χ2 test of association, with 
significant values indicated in bold
NPI Nottingham Prognostic Index, ER oestrogen receptor, PgR progesterone receptor, Her-2 epidermal 
growth factor receptor 2, LI lymphatic vessel invasion
a Numbers of analysed cases are different from total number of patients due to random core dropout during 
IHC staining process. No associations were performed with BI due to limited number of BI positive cases 
(n = 3, Table 1)
Variable IL-6 expression (n = 1191a) IL-10 expression (n = 878a)
Low High value P value (X2 value) Low High P value (X2 value)
Age (years)
 ≤ 40 83 21 0.033 (4.566) 73 10 0.22 (1.164)
 > 40 759 328 655 140
Size (cm)
 ≤ 2 490 232 0.006 (7.576) 424 94 0.361 (0.833)
 > 2 348 114 299 56
Tumour stage
 I 488 223 0.139 (3.946) 405 96 0.177 (3.466)
 II 270 95 245 40
 III 80 28 74 14
Tumour grade
 I 118 77 0.001 (13.326) 114 38 < 0.001 (29.247)
 II 277 115 227 69
 III 443 154 382 43
NPI
 < 3.4 218 127 < 0.001 (16.140) 192 67 < 0.001 (19.741)
 3.4–5.4 445 169 372 61
 > 5.4 174 49 158 22
Basal status
 Non-basal 628 259 0.783 (0.076) 542 119 0.205 (1.605)
 Basal 160 69 143 23
ER status
 Negative 221 72 0.046 (3.984) 201 21 < 0.001 (12.895)
 Positive 598 265 502 126
PgR status
 Negative 360 103 < 0.001 (19.688) 310 36 < 0.001 (17.349)
 Positive 437 230 383 104
Her-2 status
 Negative 710 298 0.762 (0.092) 606 138 0.003 (8.588)
 Positive 116 46 109 9
Triple negative (TN)
 Non-TN 671 291 0.062 (3.483) 570 131 0.003 (8.868)
 TN 149 46 136 13
LI
 Negative 457 197 0.287 (1.123) 385 87 0.192 (1.701)
 Positive 250 92 211 36
 Positive 3 0 2 1
LN status
 Negative 431 197 0.136 (2.225) 362 85 0.109 (2.566)
 Positive 307 114 296 51
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all markers in terms of BCSS (except for age, P = 0.03), 
and P < 0.001 for all markers in terms of DFS [except for 
age and ER status where P values were 0.002 and 0.004, 
respectively)]. Expression of IL-6 was not an independent 
prognostic factor for DFS [hazard ratio (HR) = 0.788; 95% 
confidence interval (CI) = 0.603–1.029; P = 0.08], or BCSS 
(HR = 0.852; 95% CI = 0.627–1.157; P = 0.305) (Supple-
mentary Table 1). Similarly, IL-10 expression was not an 
independent prognostic factor for DFS (HR = 0.799; 95% 
CI = 0.543–1.175; P = 0.254) (Supplementary Table 1).
Survival analysis of IL-6 and IL-10 expression based 
on median values as cut-points did not show prognostic 
significance for either cytokine in terms of BCSS and DFS 
(all P values were > 0.05, data not shown).
IL‑6/IL‑10 expression and survival in breast cancer 
subgroups
Survival analysis was performed in basal-like (negative for 
ER, PgR and Her-2 and positive for cytokeratins CK5/6 and 
CK14 and/or EGFR [28]) and non-basal phenotype, and in 
receptor-positive and receptor-negative disease subgroups 
to assess the significance of IL-6 and IL-10 expression in 
terms of DFS and BCSS.
Fig. 4  Kaplan–Meier analysis of association between IL-6 and IL-10 
expression with breast cancer prognosis. High IL-6 expression is sig-
nificantly associated with improved disease-free survival (P = 0.007, 
a) and improved breast cancer-specific survival (P = 0.017, b). High 
IL-10 expression is significantly associated with improved disease-
free survival (P = 0.027, c) but not breast cancer-specific survival 
(P = 0.150, d). Significance was determined using the log-rank test. 
Black represents high expression and grey represents low expression 
of the cytokine
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High IL-6 expression was significantly associated with 
DFS in non-basal (P = 0.004), non-TN disease (P = 0.003), 
ER-positive (P = 0.025), and Her-2-negative (P = 0.026) 
BC (Supplementary Fig. 1a–d, respectively). IL-6 expres-
sion was not associated with survival of BC patients with 
basal-like disease (P = 0.189), ER-negative (P = 0.212), 
PgR-positive (P = 0.103), PgR-negative (P = 0.056), Her-
2-positive (P = 0.074) nor with the TN (P = 0.687) BC. 
IL-10 expression was also associated with better DFS in 
non-basal samples (P = 0.011), non-TN (P = 0.015), ER-
positive (P = 0.039), and PgR-positive (P = 0.029) (Supple-
mentary Fig. 2a–d, respectively) cancers but not with the 
basal (P = 0.980), ER-negative (P = 0.801), PgR-negative 
(P = 0.835), Her-2-positive (P = 0.144), Her-2-negative 
(P = 0.135), or TN (P = 0.760) samples. The observed sig-
nificance with different subgroups was not maintained in 
multivariate analysis (data not shown).
High IL-6 expression was significantly associated with 
better BCSS in non-basal-like phenotype (P = 0.008) non-
TN (P = 0.002) and ER-positive disease (P = 0.041) (Sup-
plementary Fig. 3a–c, respectively) but not with the other 
subgroups. No significant associations were seen between 
IL-10 expression and BCSS in any of the histopathological 
subgroups.
The co-expression of IL-6 and IL-10 in the total cohort 
of patients was grouped into four categories (high IL-6/
high IL-10, high IL-6/low IL-10, low IL-6/high IL-10, low 
IL-6/low IL-10, n = 689). DFS and BCSS of patients in the 
four different groups was analysed, however, no significant 
associations were obtained (DFS: P = 0.206 and BCSS: 
P = 0.249, data not shown).
Discussion
Previously published data regarding the role of IL-6 and 
IL-10 in BC mostly investigated levels in serum or in whole 
tissue extracts without focusing on tumour tissue localisa-
tion. Expression of IL-6 and IL-10 (macrophage-associated 
cytokines) in tumour tissue has only been determined in a 
few studies and using relatively small patient cohorts [7–9, 
19, 29–32] with limited information about prognostic sig-
nificance (e.g. 108 invasive BC cases stained for IL-6 and 
other cytokines [33]). The current study aimed to investi-
gate the potential role(s) that IL-6 and IL-10 may play in 
the metastatic process in vitro and examine IL-6 and IL-10 
expression in BC tissues to determine their association with 
clinicopathological parameters and prognostic significance.
IL-6 has been shown to increase T47D and MDA-
MB-231, but not MCF-7, transmigration when used as a 
chemoattractant in Boyden Chamber-based assays (IL-6 
concentrations used ranged between 10 and 200 ng/mL) 
[34]; however, the direct stimulation of BC cell lines with 
IL-6 did not alter the migratory ability of MDA-MB-231 and 
MCF-7 cells in the current study. The effect of IL-6 on cell 
migration may be cell-type dependent and varies between 
in vitro and in vivo models of BC [35]. The current in vitro 
data support the findings of the IHC data where no associa-
tion was found between IL-6 expression and LN metastasis 
or LVI positivity.
Little is known about the effect of IL-10 on human cancer 
cell line migration. Previous studies showed that migration 
and invasion of HT-29 cell line was not significantly changed 
following treatment with IL-10 [36], however, in murine 
models of breast and melanoma cancers IL-10 showed 
anti-metastatic effects [37]. The effect of rIL-10 on BC cell 
migration and invasion has not been previously reported. 
Results of the current study suggest that IL-10 may inhibit 
migration of MDA-MB-231 in a dose-dependent manner. A 
similar trend was seen with MCF-7 migration, which was 
slightly decreased with IL-10 treatment for 24 h, albeit non-
significant. The control migration rate of MCF-7 was slower 
than MDA-MB-231. Therefore, it is possible that MCF-7 
cells may require a longer migration follow-up time (e.g. 
48–72 h) to observe significant inhibition of migration fol-
lowing IL-10 treatment. The inhibitory effects of IL-10 on 
tumour progression have previously concentrated on the 
anti-tumour immune effects; one of the suggested mecha-
nisms is via inducing infiltration and activation of cytotoxic 
CD8 cells [38]. In contrast to this proposed role, IL-10 pro-
duction is associated with T cell inactivation and impairment 
of adaptive immunity [39] via a direct effect on Th17 and 
Th17 and Th1 cells [40]. The complex role IL-10 plays in 
determining the immune response seems to be dependent 
on the tissue microenvironment and the expression of IL-10 
receptors on different types of immune cells [18].
Previous data suggested that IL-6 is associated with 
metastasis and the stromal IL-6 expression is key for this 
process [35, 41]. The effect of EC stimulation with IL-6, 
and IL-10, on tumour–endothelial cell adhesion was inves-
tigated in this study. Tumour cell adhesion patterns to both 
IL-6 and IL-10 stimulated hMEC-1 and hTERT-LEC were 
unaltered. Similar results have been reported with pancreatic 
carcinoma cells adhesion to hMEC-1 stimulated with IL-6 
[42]; however, as far as we are aware no published data is 
available investigating the effect of IL-10 on tumour cell 
adhesion.
The significance of IL-6 and IL-10 expression in BC 
was further investigated in a large cohort of well charac-
terised early stage invasive BC patients with long-term 
clinical follow-up. Previous studies looking at expression 
of IL-6 and IL-10 showed similar cytoplasmic expression 
patterns in tumour cells of the breast and other tumour 
types [7–9, 19, 29–33]. IL-10 expression has been shown 
to associate with improved survival rates of patients with 
colorectal cancer [32] and BC [43], but with poor survival 
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in non-small cell lung cancer [44] and gastric cancer [19]. 
IL-6 has been linked with malignancy across a number of 
different tumour types [10, 29, 34], with its importance 
being related to downstream signalling via STAT3 acti-
vation. Similar to current results, nuclear expression of 
phosphorylated STAT3 (p-STAT3, the activated form of 
STAT3) has also been recently shown to be associated with 
small tumour size, low grade and negative LVI and to be a 
positive prognosticator of BCSS [27]. When the relation-
ship between the expression of IL-6/IL-10 and p-STAT3 
was examined there was a positive correlation between 
IL-6/IL-10 and STAT3 expression. Moreover, there was 
also a positive correlation between IL-6 and IL-10 expres-
sion. It should be remembered, however, that such statisti-
cal correlations are based on protein expression rather than 
functional assays looking at activation of STAT3 by IL-6/
IL-10. The conflicting data regarding the role of IL-6 may 
suggest further consideration being given to investigating 
IL-6 mediated and IL-6 inhibitory pathways in BC.
In the current study, high IL-6 expression was asso-
ciated with good prognostic variables, i.e. lower tumour 
size, lower grade, and lower NPI value. Some of these 
results were in accordance of others, e.g. low grade and 
ER-positive tumours had high IL-6 expression [30] but 
disagree with others, e.g. Chavey et al., using whole BC 
tissue lysates, showed an inverse association between 
BC expression of IL-6 and IL-10 and ER positivity [29]. 
The difference in IL-6 assessment between the current 
study and Chavey’s study (i.e., tumoural vs. whole tissue 
lysates) may in part explain the difference in the results. 
By using tissue lysate the expression of IL-6 by stroma 
will be representative of total rather than tumoural expres-
sion of IL-16. Interestingly, there is evidence suggesting 
that ER activation inhibits STAT3 signalling in BC cell 
lines [45]. In the current study, high IL-6 expression is 
associated with ER positivity. It is possible that ER active 
signalling may inhibit autocrine downstream signalling 
in tumour cells but that it is still maintained in stromal 
cells. In those cancer types where IL-6 has been shown 
to play a pro-tumoural effect, it may well be that the ER 
pathway is less important than it is in BC. In vivo infor-
mation from murine models of TN-BC showed different 
response to STAT3 pathway blocking in vitro vs in vivo 
(i.e. IL-6 pathway inhibition did not influence tumour cell 
proliferation in vitro but potently reduced tumour growth 
using TN models of murine BC in vivo) [35]. Therefore, 
an investigation using in vivo models of ER-positive/nega-
tive tumours is warranted.
The lack of a significant relationship between IL-6 
expression with LN metastasis is in accordance with a pre-
vious BC patient study (n = 149) [30]. However, a significant 
association between IL-6 (total expression in tumour and 
stroma) and negative LN status has recently been reported 
[33] and such results support IL-6’s association with good 
prognostic markers in BC.
In terms of IL-6 survival analysis, high expression was 
associated with improved DFS and BCSS; similar to what 
has been found with IL-6 mRNA levels in BC [10], how-
ever IL-6 was not an independent prognostic factor. A recent 
study has shown that high IL-6 expression was an independ-
ent prognostic marker in terms of longer overall survival 
and DFS in BC [33], however the difference in sample size 
(n = 108 vs. 1191 in the current study) and the prognostic 
factors included in Cox regression analysis may explain the 
differences between the Fernandez-Garcia et al. paper [33] 
and current results. Furthermore, current results of the prog-
nostic significance of IL-6 in BC phenotypic subgroups sug-
gest that longer BCSS and DFS are mainly related to patient 
groups with better prognosis (i.e. non-basal-like, non-TN, 
ER-positive).
In the current study, a strong association was found 
between high IL-10 and lower tumour grade, lower NPI 
level, positive ER and PgR status, negative Her-2 expression 
as well as with the non-TN type. DFS and BCSS analysis 
of IL-10 expression in BC phenotypic subgroups suggested 
that high IL-10 expression was a marker of better prognosis 
in ER-positive, non-basal-like, non-TN. In the total cohort, 
IL-10 was also significantly associated with DFS, which 
may support the in vitro data where high levels of rIL-10 
caused a decrease in MDA-MB-231 migration. However, 
tumour expression of IL-10 was not a prognostic factor in 
terms of BCSS. Moreover, as for IL6, IL10 was not an inde-
pendent prognostic factor.
Survival analysis of IL-6/IL-10 co-classification was 
not associated with prognosis. The co-expression of three 
cytokines (i.e. IL-6/IL-10 with IL-1) was recently analysed 
against survival endpoints in BC [33]; however, only stromal 
expression, rather than tumoural expression, of the com-
bined groups showed prognostic significance. Such results 
suggest that IL-6 and IL-10 may not have a prognostic sig-
nificance in BC, but their function in modulating the tumour 
microenvironment and altering cancer cell motility and, per-
haps, metastatic ability, requires further investigation.
Conclusion
Results presented here provide an insight into the role of 
IL-6 and IL-10 in BC progression. Results demonstrate that 
high concentrations IL-10 can reduce in vitro migration, but 
do not influence adhesion to blood or lymphatic cells. High 
expression of IL-6 or IL-10 in BC tissues is significantly 
associated with some clinicopathological criteria and is also 
associated with improved DFS and BCSS in univariate but 
not in multivariate analysis. In conclusion, many contro-
versial findings remain to be elucidated and more work is 
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required to understand the downstream signalling pathways 
induced by IL-6 and IL-10 to explain the multifunctional 
roles IL-6/IL-10 play in BC.
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